|By PR Newswire||
|March 17, 2014 02:00 AM EDT||
-- Event Highlights Routine Use of The NephroCheck ® Test For AKI Risk Assessment
SAN DIEGO, March 17, 2014 /PRNewswire/ -- Globally, acute kidney injury (AKI) is a significant health threat, striking millions of hospitalized patients each year. Leading critical care experts will discuss every day use of novel biomarkers for assessing risk of AKI in the critically ill patient at an educational symposium being held on Wednesday, March 19, 2014 at 12:30 local time during the 34th International Symposium on Intensive Care and Emergency Medicine (ISICEM) in Brussels, Belgium.
Astute Medical, Inc. is sponsoring the event "New AKI biomarkers: How to use them in everyday clinical routine." Conference attendees can register for the event at AKIAssessment.com. Event participants and others can follow the live event via Twitter @ACuteKidneyMan.
AKI is a significant public hazard given its link to increased mortality and morbidity, longer intensive care unit stays, and higher in-hospital cost. Its incidence (2.1/1000 population) is similar to that of acute myocardial infarction, or heart attack.
A study recently published in the Clinical Journal of the American Society of Nephrology suggested that AKI could be more deadly than heart attack. Unlike heart attack, AKI is asymptomatic lacking warning signs such as pain, shortness of breath or other clinical symptoms, particularly in the early stages when intervention is most beneficial.
Program highlights include:
- Dr. Rinaldo Bellomo of Monash University in Australia, who will moderate the session,
- Dr. Lui Forni of Worthing Hospital in the United Kingdom, who will discuss the role of biomarkers of cell cycle arrest in regards to AKI, and
- Dr. Ivan Gocze of University Hospital Regensburg, Dr. Alex Zarbock of the University of Muenster, and Dr. Christophe Vinsonneau of Paris Descartes University, who will each present case studies describing the utilization of new AKI biomarkers in everyday routine.
Astute Medical, Inc., has developed the CE-marked NephroCheck® Test to aid in the early assessment of moderate or severe AKI risk in the critically ill. The NephroCheck® Test and the Astute140® Meter are sold in Europe. The NephroCheck® Test and the Astute140® Meter are not available in the United States.
The test utilizes fluorescence immunoassay technology to detect and measure two biomarkers of AKI, tissue inhibitor of metalloproteinase 2 (TIMP-2) and insulin-like growth factor binding protein 7(IGFBP-7) in human urine. The release of TIMP-2 and IGFBP-7 by kidney cells acts as a biological alarm signaling that the cells are acutely stressed and the kidney is at risk for AKI, which can cause permanent damage and loss of function.
The recently published Kidney Disease Improving Global Outcomes (KDIGO) Guideline for AKI recommends prompt evaluation of patients along with the implementation of kidney-sparing interventions for patients determined to be at risk and thus vulnerable to permanent damage from unchecked AKI.
Astute Medical, Inc. is an exhibitor at the ISICEM meeting, the largest and most prestigious critical care medicine conference in the world, attracting approximately 6,000 key opinion leaders, physicians, and other healthcare personnel each year. Plan to visit Astute Medical's booth located at Stand 2.66-2.68 in the main exhibit hall.
Not attending the ISICEM meeting? For more information stay connected with Astute Medical at AstuteMedical.com or via:
About Astute Medical, Inc.
Named by the Wall Street Journal as one of the Top 10 Healthcare Start-Ups of 2012, Astute Medical is dedicated to improving the diagnosis of high-risk medical conditions and diseases through the identification and validation of protein biomarkers that can serve as the basis for novel diagnostic tests. The Company's focus is community- and hospital-acquired acute conditions that require rapid diagnosis and risk assessment. Astute Medical's current areas of interest include abdominal pain, acute coronary syndromes, cerebrovascular injury, kidney injury and sepsis. For additional information, please visit AstuteMedical.com.
The NephroCheck® Test and the Astute140® Meter are not available in the United States. For information regarding trademarks and other intellectual property applicable to this product, including international trademarks, please see AstuteMedical.com/about/intellectual-property. PN 0281 Rev A 2014/02/28
Jun. 3, 2015 12:15 AM EDT Reads: 2,173
Jun. 3, 2015 12:15 AM EDT Reads: 5,650
Jun. 3, 2015 12:00 AM EDT Reads: 5,316
Jun. 3, 2015 12:00 AM EDT Reads: 1,418
Jun. 2, 2015 11:15 PM EDT Reads: 4,306
Jun. 2, 2015 11:00 PM EDT Reads: 4,466
Jun. 2, 2015 10:30 PM EDT Reads: 1,087
Jun. 2, 2015 10:15 PM EDT Reads: 4,436
Jun. 2, 2015 10:15 PM EDT Reads: 2,018
Jun. 2, 2015 10:00 PM EDT Reads: 3,412
Jun. 2, 2015 10:00 PM EDT Reads: 1,166
Jun. 2, 2015 09:30 PM EDT Reads: 1,246
Jun. 2, 2015 08:45 PM EDT Reads: 1,814
Jun. 2, 2015 08:30 PM EDT Reads: 1,730
Jun. 2, 2015 08:15 PM EDT Reads: 4,233